Modality
Small Molecule
MOA
PI3Ki
Target
VEGF
Pathway
Complement
CFHSHNSCC
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
May 2018
→ Jan 2025
Phase 1Current
NCT03493704
2,860 pts·HNSCC
2018-05→2025-01·Not yet recruiting
2,860 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-01-111.2y agoPh2 Data· HNSCC
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025
P1/2
Not yet…
Catalysts
Ph2 Data
2025-01-11 · 1.2y ago
HNSCC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03493704 | Phase 1/2 | HNSCC | Not yet recr... | 2860 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| Bemazumab | Regeneron | Phase 1 | VEGF |